Pfizer (PFE)
Health Care · Pharmaceuticals · NYSE
A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
What Pfizer does
Pfizer is a global research-based biopharmaceutical company engaged in the discovery, development, manufacturing, and marketing of medicines and vaccines. Its product portfolio spans therapeutic areas including oncology, infectious diseases, cardiovascular/metabolic health, and immunology, often marketed through its Global Biopharmaceuticals Business. The company also maintains a significant presence in mRNA technology, COVID-19 therapeutics, and specialized treatments for rare diseases like transthyretin amyloid cardiomyopathy.
Themes: mRNA technology, infectious diseases, oncology, rare diseases, vaccines, immunology
Fundamentals
- Price$28.07 as of 2026-08-21 close
- Market cap$160.0B as of 2026-08-21
- 1-year return+9.1% 2025-08-21 close $25.74 → 2026-08-21 close $28.07
- P/E35.19 as of 2026-08-24
- Net margin+6.8% as of 2026-08-24
- Gross margin+74.7% as of 2026-08-24
- ROE+4.9% as of 2026-08-24
- Debt / equity0.74 as of 2026-08-24
- Revenue growth (YoY)-0.2% as of 2026-08-24
- Revenue CAGR (3y)-14.8% SEC XBRL
- Beta0.28 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +5.4%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How PFE compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PFE is not currently in any published Top 10 list. Its scores are below.
Long-term score
40.2 #821 of 987 scored · #48 of 57 in Health Care
Capital return 71st (consecutive years of dividend increases 5 years) and long-term trend 62nd (a strong uptrend, with buyers in control); weakest is growth (9th, 3-year revenue CAGR -14.8%, revenue growth year over year -0.2%).
Short-term score
45.9 #1067 of 1,704 scored · #181 of 240 in Health Care
Trend 71st: a strong uptrend, with buyers in control; volume and participation 63rd: trading volume is about normal versus its 30-day average; weakest is setup 28th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, PFE's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 126%, free-cash-flow payout 108%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout126% dividends / net income
- Free-cash-flow payout108% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Pfizer looks technically
Pfizer (PFE) is trading 8.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 38 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 70, in overbought territory (above 70). It made a new 20-day high about 3 trading days ago. It is 2.4% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 8.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $25.36 | $25.36 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.99 | $25.99 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 38 trading days ago — a "death cross", a bearish long-term signal | 38 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 8.0% above | +8.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 38.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 70, in overbought territory (above 70) | 70.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($24.70 to $28.43) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 90.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 31 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.75 | $28.75 |
|---|---|---|
| From the 52-week high | it is 2.4% below its 52-week high (its highest price of the past year) | -2.4% |
| Above the 52-week low | it is 19.0% above its 52-week low (its lowest price of the past year) | +19.0% |
| Below the 52-week high | it is 2.4% below its highest point of the past year | 2.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $61.71 (set on 2021-12-20) | $61.71 |
| Given back of the 52-week move | over the past year its closes ranged ($23.60 to $28.55), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.33 to $25.49. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.7% |
| From the all-time high | it is 54.5% below its all-time high | -54.5% |
| Nearest price level | it is sitting right on a resistance level at $28.19 — a price it turned at twice since 2024-09-03, most recently on 2024-10-04. Since 2024-08-21 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.4% |
| All-time low | its lowest closing price on record is $0.4274 (set on 1974-10-04) | $0.4274 |
| Above the all-time low | it is 6467.0% above its all-time low | +6,467% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6071 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6071 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.15 and $28.45 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.15 – $26.30 – $28.45 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.2% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (8.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.1% since the prior reading | -0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
1
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.2 percentage points (the stock gained 12.6% while the market gained 2.3%) | +10.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 5.1 percentage points (the stock gained 8.2% while the market gained 3.1%) | +5.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.7 percentage points (the stock gained 5.3% while the market gained 11.1%) | -5.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 11.4 percentage points (the stock gained 9.1% while the market gained 20.5%) | -11.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.5% of the share price, which is taken to mean a barrier that gives way easily. | +11.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $26.11 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +7.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $26.81 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +4.7% |
Price levels it has turned at before
PFE last closed at $28.07 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $28.19 | Resistance | 0.4% above the last close | turned there twice · 2024-09-03 to 2024-10-04 |
| $27.71 | Support | 1.3% below the last close | turned there five times · 2025-01-07 to 2026-04-20 |
| $28.92 | Resistance | 3.0% above the last close | turned there three times · 2024-10-14 to 2026-04-02 |
| $27.11 | Support | 3.4% below the last close | turned there three times · 2025-01-29 to 2025-03-10 |
| $26.53 | Support | 5.5% below the last close | turned there 11 times · 2024-11-25 to 2026-06-12 |
| $30.39 | Resistance | 8.3% above the last close | turned there twice · 2024-09-19 to 2024-10-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.46 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$28.61 range $25.00 – $35.75; median $28.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PFE
- Consensus EPS estimate$0.7589 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on continued sales of COVID-19 related products like Comirnaty and Paxlovid","Exposure to government drug pricing regulations such as the Inflation Reduction Act of 2022","Complex legal and litigation risks including multi-district litigation (MDL)"]
What changed in the latest 10-Q
AI-assisted comparison of PFE's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Beginning in the first quarter of 2026, we manage our commercial operations through a global structure consisting of two operating segments: Biopharma and PC1 (newer filing, 2026-05-05)
- Removed:
- Our 2025 key priorities section including four strategic priorities (improve R&D productivity, expand margins, achieve commercial excellence, optimize capital allocation) (older filing, 2025-11-04)
- Reference to digital enablement, automation and AI as efficiency mechanisms in strategic context (older filing, 2025-11-04)
- Three operating segments structure: Biopharma, PC1 and Pfizer Ignite (older filing, 2025-11-04)
- Entire Restructuring Programs section including details of Realigning Our Cost Base Program and Manufacturing Optimization Program (older filing, 2025-11-04)
- References to fourth quarter 2023 cost realignment program announcement (older filing, 2025-11-04)
- References to first and second quarter 2025 productivity initiatives and digital enablement efforts (older filing, 2025-11-04)
- Reworded:
- Section heading changed from 'OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK' to 'OVERVIEW OF OUR PERFORMANCE, OPERATING AND GLOBAL ECONOMIC ENVIRONMENT' (newer vs older filing)
- Notes:
- The newer filing text appears truncated at 'For additional information about our business, strategy and operating environment, see the' - comparison is limited to the available portion
- Older filing contains substantially more detailed content on restructuring programs and strategic priorities that is entirely absent from the newer filing excerpt
Risk Factors
- Added:
- Added 'GILTI (NCTI)' definition in newer filing (2026-05-05): 'Global Intangible Low-Taxed Income (renamed Net Controlled Foreign Corporation (CFC) Tested Income (NCTI) for taxable years starting after December 31, 2025)'
- Added 'GSK' definition in newer filing (2026-05-05): 'GSK plc'
- Added 'Sciwind Biosciences' definition in newer filing (2026-05-05): 'Hangzhou Sciwind Biosciences Co., Ltd.'
- Removed:
- Removed 'AbbVie' definition from older filing (2025-11-04): 'AbbVie Inc.'
- Removed 'Abingworth' definition from older filing (2025-11-04): 'Abingworth LLP'
- Removed 'ACIP' definition from older filing (2025-11-04): 'Advisory Committee on Immunization Practices'
- Removed 'CDC' definition from older filing (2025-11-04): 'U.S. Centers for Disease Control and Prevention'
- Removed 'CMS' definition from older filing (2025-11-04): 'Centers for Medicare & Medicaid Services'
- Removed 'DMD' definition from older filing (2025-11-04): 'Duchenne muscular dystrophy'
- Removed 'HIPAA' definition from older filing (2025-11-04): 'Health Insurance Portability and Accountability Act of 1996'
- Removed 'Meridian' definition from older filing (2025-11-04): 'Meridian Medical Technologies, Inc.'
- Removed 'NDA' definition from older filing (2025-11-04): 'New Drug Application'
- Removed 'Ono' definition from older filing (2025-11-04): 'Ono Pharmaceutical Co., Ltd.'
- Removed 'Pierre Fabre' definition from older filing (2025-11-04): 'Pierre Fabre Medicament SAS'
- Removed 'PNIF' definition from older filing (2025-11-04): 'Pfizer Netherlands International Finance B.V. (a wholly-owned finance subsidiary of Pfizer)'
- Removed 'QTD' definition from older filing (2025-11-04): 'Quarter-to-date or three months ended'
- Removed 'SCD' definition from older filing (2025-11-04): 'sickle cell disease'
- Removed 'YTD' definition from older filing (2025-11-04): 'Year-to-date or nine months ended'
- Removed 'Blackstone' definition from older filing (2025-11-04): 'Blackstone Life Sciences'
- Removed reference to '2024 Form 10-K' from older filing (2025-11-04); replaced with '2025 Form 10-K' in newer filing
- Reworded:
- Changed fiscal quarter-end description from 'three and nine months ended August 24, 2025 and August 25, 2024' (older, 2025-11-04) to 'three months ended February 22, 2026 and February 23, 2025' (newer, 2026-05-05) for non-U.S. subsidiaries
- Changed fiscal quarter-end description from 'three and nine months ended September 28, 2025 and September 29, 2024' (older, 2025-11-04) to 'three months ended March 29, 2026 and March 30, 2025' (newer, 2026-05-05) for U.S. subsidiaries
- Changed reference from '2024 Form 10-K' (older, 2025-11-04) to '2025 Form 10-K' (newer, 2026-05-05)
- Changed Form 10-Q reference from 'quarterly period ended September 28, 2025' (older, 2025-11-04) to 'quarterly period ended March 29, 2026' (newer, 2026-05-05)
- Changed 'Developed Markets' definition to remove 'certain Eastern European countries' and 'Nordic countries' from older version and replace with 'Central Europe' and 'Nordic countries' in newer version; also changed 'Australia' positioning and modified references to include 'Canada' and 'New Zealand'
- Changed 'Emerging Markets' definition from 'Eastern Europe (excluding the Balkans)' (older, 2025-11-04) to 'Eastern Europe (excluding the Balkans and certain other countries)' (newer, 2026-05-05)
- Changed reference from 'our X (formerly known as Twitter) accounts' (older, 2025-11-04) to 'our X accounts' (newer, 2026-05-05)
- Item page number changed from 57 (older, 2025-11-04) to 46 (newer, 2026-05-05) for Risk Factors
- Notes:
- The two filings are from different quarterly periods (Q3 2025 vs Q1 2026), which explains changes in fiscal quarter-end dates and related references
- The text provided appears truncated, particularly at the end of the financial statements section, limiting ability to assess changes in that portion
- Some removals may reflect terms that were relevant to the earlier quarter but are not included in the current quarter's filing rather than deliberate deletions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
3 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 30 days3 buys ($3M) · 1 sell ($83261) — 3 buying, 1 selling insiders
- Last 90 days3 buys ($3M) · 2 sells ($134661) — 3 buying, 1 selling insiders
- Last 180 days3 buys ($3M) · 2 sells ($134661) — 3 buying, 1 selling insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of PFE within a 30-day window between 2026-08-05 and 2026-08-12. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PFE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 25 matched disclosures for PFE from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding PFE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 840,820,638
- Reported value $23,610,243,509
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PFE had 161,478,227 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PFE had 2.83% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.18 days to cover at the same settlement.
- Reported short interest (shares) 161,478,227
- Short interest (% of shares outstanding) 2.83%
- Prior settlement (shares) 163,820,439
- Reported change -1.43%
- Days to cover (reported) 4.18
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GSK (GSK)
- Bristol-Myers Squibb (BMY)
- Astellas Pharma (ALPMY)
- Takeda Pharmaceutical (TAK)
- BioNTech (BNTX)
- Innovent Biologics (IVBIY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PFE vs…
Pfizer is found in…
PFE shows up in…
Frequently asked questions
What does Pfizer (PFE) do?
Pfizer is a global research-based biopharmaceutical company engaged in the discovery, development, manufacturing, and marketing of medicines and vaccines. Its product portfolio spans therapeutic areas including oncology, infectious diseases, cardiovascular/metabolic health, and immunology, often marketed through its Global Biopharmaceuticals Business.
What sector is Pfizer (PFE) in?
Pfizer (PFE) is classified in the Health Care sector. Its industry is Pharmaceuticals. It trades on NYSE.
Does PFE pay a dividend?
Yes — Pfizer (PFE) pays a dividend, with an indicated yield of about 5.38% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Pfizer's (PFE) competitors?
Notable peers of Pfizer (PFE) include GSK, Bristol-Myers Squibb, Astellas Pharma, Takeda Pharmaceutical and BioNTech. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in PFE?
Yes — we hold 25 matched STOCK Act disclosures for PFE from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Pfizer (PFE) overbought or oversold right now?
Pfizer (PFE) is currently in overbought territory (its 14-day RSI is 70, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PFE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.